US 9408839
Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
granted A61KA61K31/454A61P
Quick answer
US patent 9408839 (Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype) held by VANDA PHARMACEUTICALS INC. expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VANDA PHARMACEUTICALS INC.
- Grant date
- Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/454, A61P, A61P25/18